Latest News Year 2024 2023 2022 2021 2020 2019 2018 2017 2016 Search Senhwa Signs Agreement with Taiwan’s CDE for COVID-19 Program Guiding Development of Silmitasertib Aug 11 2021 Senhwa Announces IND Submission to India's CDSCO of a Phase II Clinical Study for Silmitasertib as a Potential COVID-19 Treatment Jun 23 2021 Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference Sep 27 2021 Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial of Silmitasertib as a Treatment for Patients with Severe COVID-19. Jan 22 2021 Senhwa Biosciences Presents Positive Cholangiocarcinoma Data. Jan 15 2021 Senhwa Biosciences Receives US FDA ‘Study May Proceed’ Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461 Dec 24 2020 Senhwa Biosciences’s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium Dec 14 2020 Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial of Silmitasertib as a Treatment for COVID-19 Dec 03 2020 1 2 3 4 5 6 7 8